Name: | Aztreonam |
---|---|
PubChem Compound ID: | 10884593 |
Description: | A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. |
Molecular formula: | C13H17N5O8S2 |
Molecular weight: | 435.435 g/mol |
Name: | Aztreonam |
---|---|
Name (isomeric): | DB00355 |
Drug Type: | small molecule |
Description: | A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. |
Synonyms: |
AZT
|
Brand: | Dynabiotic, Monobactam, Corus 1020, Primbactam, Azactam |
Category: | Anti-Bacterial Agents |
CAS number: | 78110-38-0 |
Indication: | For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections. |
---|---|
Pharmacology: |
Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum. Aztreonam exhibits potent and specific activity in vitro against a wide spectrum of gram-negative aerobic pathogens including Pseudomonas aeruginosa. It has no useful activity against gram-positive bacteria or anaerobes,...
show more » |
Mechanism of Action: |
The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as ...
show more » |
Absorption: | Less than 1% absorbed from the gastrointestinal tract following oral administration. Completely absorbed following intramuscular administration. |
Protein binding: | Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%. |
Biotransformation: | Approximately 6 to 16% metabolized to inactive metabolites by hydrolysis of the beta-lactam bond, resulting in an open-ring compound. |
Route of elimination: | In healthy subjects, aztreonam is excreted in the urine about equally by active tubular secretion and glomerular filtration. Urinary excretion of a single parenteral dose was essentially complete by 12 hours after injection. |
Half Life: | The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively). |
Clearance: | 91 mL/min [healthy] |
Affected organisms: | Enteric bacteria and other eubacteria |
Drug interaction: |
|
---|